EA006604B1 - Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции - Google Patents

Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции Download PDF

Info

Publication number
EA006604B1
EA006604B1 EA200300183A EA200300183A EA006604B1 EA 006604 B1 EA006604 B1 EA 006604B1 EA 200300183 A EA200300183 A EA 200300183A EA 200300183 A EA200300183 A EA 200300183A EA 006604 B1 EA006604 B1 EA 006604B1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
agonist
antagonist
ethoxy
receptor antagonist
Prior art date
Application number
EA200300183A
Other languages
English (en)
Russian (ru)
Other versions
EA200300183A1 (ru
Inventor
Сукхвиндер Джоссан
Бьерн М. Нильссон
Хьелль С. Сакариассен
Ян Свартенгрен
Original Assignee
Биовитрум Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовитрум Аб filed Critical Биовитрум Аб
Publication of EA200300183A1 publication Critical patent/EA200300183A1/ru
Publication of EA006604B1 publication Critical patent/EA006604B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EA200300183A 2000-07-21 2001-07-19 Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции EA006604B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (2)

Publication Number Publication Date
EA200300183A1 EA200300183A1 (ru) 2003-08-28
EA006604B1 true EA006604B1 (ru) 2006-02-24

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300183A EA006604B1 (ru) 2000-07-21 2001-07-19 Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции

Country Status (19)

Country Link
EP (1) EP1301476A1 (pl)
JP (1) JP2004504376A (pl)
KR (1) KR100845450B1 (pl)
CN (1) CN1221254C (pl)
AU (2) AU8273401A (pl)
BR (1) BR0112661A (pl)
CA (1) CA2411192A1 (pl)
EA (1) EA006604B1 (pl)
HK (1) HK1057536A1 (pl)
HU (1) HUP0301346A3 (pl)
IL (1) IL154057A0 (pl)
MX (1) MXPA03000548A (pl)
NO (1) NO20030304L (pl)
NZ (1) NZ523216A (pl)
PL (1) PL360309A1 (pl)
SE (1) SE0002754D0 (pl)
WO (1) WO2002008178A1 (pl)
YU (1) YU2603A (pl)
ZA (1) ZA200210234B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
KR100822655B1 (ko) * 2000-11-02 2008-04-17 와이어쓰 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
WO2002102774A1 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
CN1826322B (zh) 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2020230B1 (en) * 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
MY157497A (en) 2009-06-15 2016-06-15 Takeda Pharmaceutical Pyrazinooxazepine derivatives
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
PL360309A1 (pl) 2004-09-06
YU2603A (sh) 2006-05-25
HK1057536A1 (en) 2004-04-08
BR0112661A (pt) 2003-06-24
EA200300183A1 (ru) 2003-08-28
SE0002754D0 (sv) 2000-07-21
CN1443162A (zh) 2003-09-17
HUP0301346A3 (en) 2005-05-30
NO20030304L (no) 2003-03-12
IL154057A0 (en) 2003-07-31
MXPA03000548A (es) 2004-04-05
EP1301476A1 (en) 2003-04-16
CN1221254C (zh) 2005-10-05
KR20030036599A (ko) 2003-05-09
ZA200210234B (en) 2004-03-18
HUP0301346A2 (hu) 2003-08-28
CA2411192A1 (en) 2002-01-31
AU2001282734B2 (en) 2006-10-12
NZ523216A (en) 2005-05-27
KR100845450B1 (ko) 2008-07-10
AU8273401A (en) 2002-02-05
JP2004504376A (ja) 2004-02-12
WO2002008178A1 (en) 2002-01-31
NO20030304D0 (no) 2003-01-20

Similar Documents

Publication Publication Date Title
EA006604B1 (ru) Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
US8003669B2 (en) Remedy for sleep disturbance
EP1949902B1 (en) USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
EP1988076A1 (en) Amide derivative or salt thereof
BG63487B1 (bg) Използване на хетероциклени съединения
DK3077391T3 (en) USE OF BENZIMIDAZOLE PROLINE DERIVATIVES
SK287828B6 (sk) 5-Halo-tryptamine derivatives used as ligands of 5-HT6 and/or 5-HT7 serotonin receptors
KR102613179B1 (ko) Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
TW201120042A (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CA2167004C (en) Agent for treating mental disorders associated with cerebrovascular disorders
KR20090069316A (ko) Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
US20080138413A1 (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
JPWO2012161301A1 (ja) ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
AU775591B2 (en) Anxiety method
TW406083B (en) Novel piperazine derivatives
US20130338116A1 (en) Compounds and methods for the treatment of pain and other diseases
JPH05507933A (ja) Ｃｎｓおよび抗高血圧活性を有する置換１―（アルコキシフェニル）ピペラジン類
CN1938020A (zh) 离子通道调节剂
EP1707206A1 (de) Piperazinderivate zur inhibition von Beta-Sekretase, Cathepsin D, Plasmepsin ll und HIV-Protease und zur Behandlung von Malaria, Alzheimer und AIDS
EP0621781A1 (en) Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses
CA3230779A1 (en) Asymmetric allyl tryptamines
PL173812B1 (pl) Środek farmaceutyczny do leczenia zaburzeń ośrodkowego układu nerwowego
TW200412968A (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU